Norgalax

Norgalax contains the active ingredient Docusate Sodium 0.12 gin each 10g micro-enema.

Rectal gel.

For the symptomatic treatment of constipation whenever an enema is required and for the preparation of the colon and rectum for endoscopic examination.

Adults: use one micro-enema. If required, a second micro-enema may be used on the same or the next day.

Children:

not recommended for children under 12 years old.

Norgalax is to be administered rectally. Remove the protective cap and insert the applicator in to the rectum, squeezing gently until the tube is empty. A drop of the gel maybe used as a lubricant if required.

Haemorrhoids, anal fissures, rectocolitis, anal bleeding, abdominal pain, intestinal obstruction, nausea, vomiting, inflammatory bowel disease, ileus and known hypersensitivity to any of the ingredients.

As with all laxatives, Norgalax should not be administered chronically. Prolonged use can precipitate the onset of an atonic non- functioning colon and hypokalaemia.

Norgalax may increase the resorption of medicines and is not to be used in combination with hepatotoxic agents.

Pregnancy

There are no adequate data from the use of docusate enema or oral docusate in pregnant women. Animal studies with oral docusate are insufficient with respect to effects on pregnancy and embryonic foetal development.

The potential risk for humans is unknown. As minimal systemic absorption cannot be ruled out following rectal application, Norgalax should be used in pregnancy only if the benefits outweigh the risks.

Lactation

It is unknown whether docusate is excreted in human breast milk. Animal studies have shown excretion of docusate and its metabolites in breast milk when administered systemically. A decision on whether to continue/discontinue breast-feeding or continue/discontinue therapy with NORGALAX should be made taking into account the benefit of breast-feeding to the child and the benefit of NORGALAX therapy to the woman.

None known.

Gastrointestinal disorders: anal burning, rectal pain, rectal bleeding, diarrhoea

Skindisorders: urticaria

Hepaticdisorders: cases of hepatotoxicity have been reported with oral intake of docusate taken together with other laxatives.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Overdose will lead to excessive purgation which should be treated symptomatically.

Docusatesodium is an anionic surfactant and used as a faecal softening agent. It is considered to ease constipation by increasing the penetration of fluid into the faeces thereby causing them to soften. Norgalax is usually effective in 5 to 20 minutes.

Norgalax has a local effect in the rectum. Minimal absorption cannot be ruled out even with a rectal application.

Non-clinical data reveal no special hazard for humans based on studies of acute toxicity, repeated dose toxicity and in-vitro genotoxicity. Docusate sodium has been shown to exhibit developmental toxicity in rodents at oral doses that are maternally toxic and sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. High oral doses given during lactation reduced pup weight and survival which was attributed to docusate and its metabolites present in the milk of the dams.

Glycerol

Sodium carboxymethylcellulose

Purified Water

None known

3 years

Do not store above 25°C.

A polyethylene tube with fixed applicator and a cap closure, containing 10g of gel in pack sizes of 6 and100 tubes.

None.

Essential Pharma

7 Egham Business Village

Crabtree Road

Egham, Surrey

TW20 8RB

United Kingdom

PL 41871/0007

18/01/2005

21/09/2015